Doseology Files Annual Information Form (AIF), Strengthening Public Disclosure Record AIF Filing Enhances Transparency and Provides Consolidated Disclosure for Investors

KELOWNA, BC, Jan. 16, 2026 /PRNewswire/ — Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) (“Doseology” or the “Company”) a leader in biotechnology-driven consumer products, today announced that it has filed its Annual Information Form (“AIF“), a key Canadian public-company disclosure document, for the fiscal year ended June 30, 2025 on SEDAR+.

The filing of the AIF reflects Doseology’s continued focus on maintaining strong public-company disclosure practices and provides investors with a consolidated reference covering the Company’s business, strategy, risk factors, governance practices, and capital structure.

Enhanced Transparency for Investors

The AIF consolidates information that is otherwise distributed across multiple disclosure documents into a single, structured filing intended to improve accessibility and usability for shareholders and the broader investment community. Management believes that clear, well-organized disclosure supports informed analysis and long-term investor understanding of the Company.

“High-quality disclosure is not just a regulatory requirement — it is a critical part of how we build trust with shareholders over time,” said Chris Jackson, Chief Executive Officer of Doseology.

“Filing our AIF reflects our commitment to clarity, consistency, and discipline in how we communicate as a public company, while continuing to focus on thoughtful execution of our strategy.”

Governance Discipline and Capital Markets Context

Maintaining an up-to-date AIF is a standard component of public-company governance and forms part of Doseology’s broader approach to responsible stewardship and regulatory compliance. While the Company regularly evaluates strategic, operational, and financing alternatives in the ordinary course of business, the filing of an AIF does not constitute an application for, or assurance of, short-form prospectus eligibility, nor does it represent a decision to pursue any public offering or financing at this time.

By maintaining a current disclosure record, the Company seeks to preserve flexibility under Canadian securities laws should future circumstances warrant, subject to regulatory requirements, market conditions, and internal approvals.

No Financing Announced

No financing transaction, public offering, or capital markets activity is being announced as a result of this filing. Any future financing, if undertaken, would be evaluated carefully in light of prevailing market conditions, regulatory considerations, and the Company’s long-term strategic priorities. Notwithstanding, one of the motivations for the filing of the AIF is to enable to Corporation to be short form prospectus eligible pursuant to National Instrument 44-101 – Short Form Prospectus Distributions.

Why Now

Doseology filed its AIF to consolidate disclosure as the Company’s operating profile has evolved, including platform development and its first acquisition. Management viewed this as the appropriate point to provide investors with a clearer, single reference reflecting the Company’s current scope, risks, and governance practices. The filing is process-driven and not connected to any financing or capital markets transaction.

Availability of Disclosure

The Company’s AIF and other continuous disclosure documents are available under Doseology’s profile on SEDAR+ at www.sedarplus.ca.

About Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)

Doseology Sciences Inc. operates in the oral stimulant sector as a next-generation platform intended to reshape how consumers access energy, stimulation, and nutraceutical products through better-for-you formats. The Company emphasizes product innovation, intellectual property development, capacity ownership, and disciplined commercial execution, and pursues measured growth and scalability through internal development and selective strategic acquisitions.

For more information:

https://doseology.com
https://feedthatbrain.com

On behalf of the Board of Directors, Chris Jackson
CEO, Director
Doseology Sciences Inc.

For more information, please contact the Company at:
Email: hello@doseology.com
Phone: 604.908.3095

Forward Looking Statements

This press release contains statements that constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; and compliance with government regulation and related costs.. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release.

Logo: https://mma.prnewswire.com/media/2858641/5721412/Doseology_Sciences_Inc_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/doseology-files-annual-information-form-aif-strengthening-public-disclosure-record-aif-filing-enhances-transparency-and-provides-consolidated-disclosure-for-investors-302663532.html

SOURCE Doseology Sciences Inc.